Definium Therapeutics, Inc. announced positive topline data from its Phase 3 Emerge study of DT120 ODT for the treatment of major depressive disorder. The company released a press release and a presentation discussing the results of the study. Definium Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for mental health disorders.
